文献速递新生儿儿童神经与发育行为

可溶性LOX-1作为新生儿缺氧缺血性脑病新型生物标志物的初步研究

A Pilot Study of Soluble Form of LOX-1 as a Novel Biomarker for Neonatal Hypoxic-Ischemic Encephalopathy.
PubMed 文献 · J Pediatr · 2018-12-12

该观察性研究纳入27例胎龄≥36周、出生体重≥1800g的缺氧缺血性脑病(HIE)患儿和45例对照婴儿,评估血浆可溶性凝集素样氧化低密度脂蛋白受体-1(sLOX-1)水平与HIE严重程度及预后的关系。结果显示,出生后6小时内sLOX-1水平与HIE严重程度相关,可区分中重度与轻度HIE,并在接受治疗性低温的患儿中预测无神经感觉损伤的完整生存。

要点

  • 出生后6小时内血浆sLOX-1水平与HIE严重程度相关。
  • sLOX-1≥550 pg/mL区分中重度与轻度HIE的灵敏度80.0%、特异度83.3%。
  • 治疗性低温患儿中sLOX-1<1000 pg/mL区分完整生存与死亡或神经感觉损伤,特异度100%。

核心结论

  • sLOX-1可能作为新生儿HIE严重程度分期和结局预测的有用生物标志物。
  • 需进一步研究以促进其临床应用。

研究设计与样本

  • 观察性研究,纳入27例HIE患儿和45例对照婴儿,胎龄≥36周且出生体重≥1800g。
  • HIE标准为出生后60分钟内pH≤7.0或碱缺失≥16 mmol/L,且10分钟Apgar评分≤5或复苏时间≥10分钟。
  • 采用改良Sarnat分期评估HIE严重程度,测量血浆sLOX-1水平,评估出院时一般和神经系统体征,无神经感觉损伤者归类为完整生存。

主要发现

  • 出生后6小时内sLOX-1水平与HIE严重程度相关。

关键数值与推荐

  • sLOX-1 cutoff值≥550 pg/mL区分中重度与轻度HIE的灵敏度80.0%、特异度83.3%。
  • 治疗性低温患儿中sLOX-1 cutoff值<1000 pg/mL区分完整生存与死亡或神经感觉损伤,特异度100%且阳性预测值高。

临床怎么用

  • sLOX-1或可用于出生后6小时内辅助判断HIE严重程度。
  • 在治疗性低温患儿中,sLOX-1<1000 pg/mL可能提示完整生存概率高。
  • 目前尚属初步研究,临床应用需进一步验证。

局限性

  • 本研究为初步研究,样本量较小(HIE患儿27例,对照45例)。
  • 原文未报告多中心验证或长期随访结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the soluble form of lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) as a biomarker of severity staging and prognosis in neonatal hypoxic-ischemic encephalopathy (HIE). STUDY DESIGN: We performed an observational study enrolling 27 infants with HIE and 45 control infants of gestational age ≥36 weeks and birth weight ≥1800 g. The HIE criteria were pH ≤7.0 or a base deficit ≥16 mmol/L within 60 minutes after birth, and a 10-minute Apgar score ≤5 or resuscitation time ≥10 minutes. HIE severity was evaluated using modified Sarnat staging. We measured plasma sLOX-1 level and assessed general and neurologic signs at discharge, and classified infants with no neurosensory impairments as intact survival. RESULTS: sLOX-1 level within 6 hours after birth was correlated with the severity of HIE. sLOX-1 differentiated moderate-severe HIE (median, 1017 pg/mL; IQR, 553-1890 pg/mL) from mild HIE (median, 339 pg/mL; IQR, 288-595 pg/mL; P = .007). The sensitivity and specificity of the differentiation with a cutoff value of ≥550 pg/mL were 80.0% and 83.3%, respectively. In 19 infants with therapeutic hypothermia, a sLOX-1 cutoff value of <1000 pg/mL differentiated intact survival (median, 761 pg/mL; IQR, 533-1610 pg/mL) from death or neurosensory impairment (median, 1947 pg/mL; IQR, 1325-2506 pg/mL; P = .019) with 100% specificity and a positive predictive value. CONCLUSION: sLOX-1 may be a useful biomarker of neonatal HIE for severity staging and outcome prediction. Further investigations will facilitate its clinical use.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Akamatsu T, Sugiyama T, Aoki Y, et al. A Pilot Study of Soluble Form of LOX-1 as a Novel Biomarker for Neonatal Hypoxic-Ischemic Encephalopathy. J Pediatr. 2018. PMID: 30553539. doi:10.1016/j.jpeds.2018.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。